Silence Therapeutics plc Effective Income Tax Rate Reconciliation, Nondeductible Expense, Research and Development, Amount
Silence Therapeutics plc (SLNCF) reported Effective Income Tax Rate Reconciliation, Nondeductible Expense, Research and Development, Amount of $7.88 million for the 12-month period ending 2025-12-31, per its 10-K filed 2026-03-05.
Financial Statements › Expense Statement › Income Tax
us-gaap:IncomeTaxReconciliationNondeductibleExpenseResearchAndDevelopment · last filed 2026-03-05
- Silence Therapeutics plc effective income tax rate reconciliation, nondeductible expense, research and development, amount for fiscal 2025 was $7.88M.
| Period end | Effective Income Tax Rate Reconciliation, Nondeductible Expense, Research and Development, Amount 12 month |
|---|---|
| 2025-12-31 | $7.88M 10-K · filed 2026-03-05 |